Ajay K. Gopal, MD:We’re now at 5 months later with this patient who had received 2 cycles of R-CHOP and achieved a partial remission, and this patient now presents with abdominal fullness consistent with, again, progressive disease. You do a physical exam on the patient. This patient now has marked splenomegaly and thrombocytopenia. PET/CT scan shows progressive disease. And at this point, the patient actually gets a repeat biopsy and now comes back as a grade 3 follicular lymphoma. What we don’t know is whether this is a grade 3A or a grade 3B, which is really quite an important distinction. Grade 3B really is a diffuse large B-cell lymphoma, and in the current WHO classification, we would treat this as an aggressive lymphoma. And if that were the case, we would probably, if the patient was fit, give platinum-based chemotherapy, try to get the patient into a remission, and then consolidate with high-dose therapy and autotransplant. It certainly would still be a reasonable option even in a 3A, or even if this was a grade 1/2 follicular. Autotransplant is something we can consider in chemosensitive relapse. So, we don’t really know the situation here, whether this is a grade 3A or a 3B follicular lymphoma.
Another notable point is that this patient developed considerable anemia and thrombocytopenia. If you do a marrow and you see it’s packed with lymphoma, then you have an obvious explanation. However, the patient didn’t tolerate the chemotherapy very well in the past. Patient also had CMV infection. Again, that’s quite unusual at baseline, and you wonder if there’s some underlying marrow disorder with this patient and poor tolerance to chemotherapy. This patient was started on idelalisib therapy, and after about 2 months on therapy developed grade 3 colitis, which was managed. And it sounds like the patient was restarted on therapy based on the case. The patient had stable disease and is remaining on drug at the end of this case.
The question that comes up often is, what are the other choices besides idelalisib in this situation? I want to point out that there is a drug, an historical agent that we can consider maybe not for this patient because they have 90% marrow involvement, but there’s a drug called ibritumomab tiuxetan, which is a Yttrium-90labeled monoclonal antibody. Commercial name is Zevalin. In those who have less than 25% marrow involvement, we would expect about an 80% response rate. So, that’s actually a really active drug, but you have to use it when the counts are decent and the marrow is not involved. You can’t wait too long to use that drug, but in appropriate patients, that can be quite an effective drug. There’s another PI3-kinase inhibitor called copanlisib, which has recently been approved, same label, 2 prior lines of therapy. This is an IV PI3K inhibitor that is given 3 out of 4 weeks IV. So, it has a very comparable response rate, somewhat slightly different side effect profile, a little bit of hyperglycemia and hypertension following the infusion. And obviously getting an intravenous drug has a different time commitment than an oral agent.
Transcript edited for clarity.
January 2016
June 2017
November 2017
Behind the FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma
March 8th 2024Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
Read More
FDA Grants Priority Review to Epcoritamab for R/R Follicular Lymphoma
February 27th 2024If FDA-approved, epcoritamab would be the first and only subcutaneous bispecific antibody indicated for the treatment of adult patients with relapsed/refractory follicular lymphoma after 2 rounds of previous therapy.
Read More
Second-Line Liso-cel Shows Promise in High-Risk Relapsed/Refractory FL
January 12th 2024In an interview with Targeted Oncology, Franck Morschhauser, MD, PhD, discussed the high complete response rates and durable remissions seen with lisocabtagene maraleucel in patients with high-risk relapsed/refractory follicular lymphoma.
Read More
Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma
December 11th 2023Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.
Read More